Stocktoria
Tempest Therapeutics, Inc. TPST
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-10-04
Tempest Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | $295,000 | $653,000 |
| R&D expense | — | — | — | — | — | — | — | — | $18.3M | $21.6M |
| SG&A expense | — | — | — | — | — | — | — | — | $27.7M | $49.2M |
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M | -$19.3M | -$45.4M | -$26.9M | -$84.3M | -$81.0M |
| Interest expense | — | — | $1.4M | $1.6M | $1.3M | $0 | — | $134,000 | $288,000 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $67,000 | $201,000 |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M | -$28.3M | -$19.2M | -$44.6M | -$27.2M | -$84.6M | -$82.3M |
| EPS (diluted) | $-6.33 | $-19.50 | $-1.91 | $-3.09 | $-7.47 | $-41.03 | — | — | — | — |
| Operating cash flow | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M | -$19.0M | -$41.2M | -$23.6M | -$20.3M | -$61.7M |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M | -$19.1M | -$41.6M | -$23.7M | -$20.3M | -$64.3M |
| Cash & equivalents | $7.7M | $30.3M | $39.2M | $31.2M | $51.8M | $18.8M | $62.5M | $73.3M | $17.6M | $43.9M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M | $22.9M | $75.0M | $84.1M | $19.8M | $122.5M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M | $4.9M | $15.1M | $11.0M | $4.8M | $14.3M |
| Shareholders' equity | $6.7M | $19.1M | $26.8M | $18.1M | $36.1M | -$68.8M | $59.9M | $73.1M | -$130.7M | $108.2M |
Growth · year-over-year · Revenue CAGR -54.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | — | — | -54.8% | +135.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.